Optimal low-density lipoprotein cholesterol lowering - Morning versus evening statin administration

Annals of Pharmacotherapy

Volumn 41, Issue 1, 2007, Pages 106-110

  Plakogiannis, Roda ^a,b   Cohen, Henry ^a,c  

^a LONG ISLAND UNIVERSITY   (United States)

^b BELLEVUE HOSPITAL CENTER   (United States)

^c KINGSBROOK JEWISH MEDICAL CENTER   (United States)

Author keywords

Atorvastin; Dosing; Fluvastatin; Lovastatin; Pravastatin; Rosuvastatin; Simvastatin

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DATA ANALYSIS; DATA BASE; DOSAGE SCHEDULE COMPARISON; EVALUATION; HUMAN; HYPERCHOLESTEROLEMIA; LANGUAGE; MEDICAL LITERATURE; MEDLINE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLICATION; SAMPLE SIZE; SYSTEMATIC REVIEW;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CHRONOTHERAPY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA;

EID: 33846446045     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G659     Document Type: Article

References (25)

1. Pitt B, Waters D, Brown WV, et al. Aggressive lipid lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1991;341:70-6.
2. Kannel WB, Castelli WP, Gordon T, et al. Serum lipoproteins and the risk of coronary heart disease. The Framingham Study. Ann Intern Med 1971; 74:1-12.
3. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease (4S). Lancet 1995;344:1383-9.
4. Sacks FM, Pfeffer MA, Moyle LA. LIPID Study Program. N Engl J Med 1996;335:1001-9.
5. Shepherd J, Cobbe SM, Ford I. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
6. Libby P, Aikawa M. Mechanisms of plaque stabilization with statins. Am J Cardiol 2003;91(suppl):4B-8B.
7. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992;152:56-64.
8. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74.
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
10. Package insert. Mevacor (lovastatin). Whitehouse Station, NJ: Merck Pharmaceuticals, November 2004.
11. Package insert. Zocor (simvastatin). Whitehouse Station, NJ: Merck Pharmaceuticals, November 2005.
12. Package insert. Lescol (fluvastatin). East Hanover, NJ: Novartis Pharmaceuticals Corporation, May 2004.
13. Parker TS, McNamara DJ, Brown C, et al. Mevalonic acid in human plasma: relationship of concentration and arcadian rhythm to cholesterol synthesis rates in man. Proc Natl Acad Sci U S A 1982;79:3037-41.
14. Package insert. Lipitor (atorvastatin). Morris Plains, NJ: Pfizer Pharmaceuticals, July 2004.
15. Package insert. Crestor (rosuvastatin). Wilmington, DE: AstraZeneca, March 2005.
16. Package insert. Pravachol (pravastatin). Princeton, NJ: Bristol-Myers Squibb, November 2003.
17. Grundy SM, Cleeman JI, Merz NB, et al. Implications of recent clinical trials for the National Cholesterol Education Panel ATP III guidelines. Circulation 2004;110:227-39.
18. Illingworth RD. Comparative efficacy of once versus twice daily mevinolin in the therapy of familial hypercholesterolemia. Clin Pharmacol Ther 1986;40:338-43.
19. Saito Y, Yoshida S, Nakaya N, et al. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study. Arterioscler Thromb Vasc Biol 1991;11:816-26.
20. Wallace A, Chinn D, Rubin G. Taking simvastatin in the morning compared with in the evening: randomized controlled trial. BMJ 2003;327:788.
21. Hunninghake DB, Mellies MJ, Goldberg AC, et al. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 1990;85:219-27.
22. Cilla DD, Gibson DM, Whitfield LR, et al. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol 1996;36:604-9.
23. Plakogiannis R, Cohen H, Taft D. Effects of morning versus evening administration of atorvastatin in patients with hyperlipidemia. Am J Health Syst Pharm 2002;62:2491-4.
24. Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol 2002;54:472-7.
25. Insull W, Black D, Dujovne C, et al. Efficacy and safety of once-daily vs twice-daily dosing fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia. Arch Internal Med 1994;154:2449-55.